JP2007530584A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530584A5
JP2007530584A5 JP2007505204A JP2007505204A JP2007530584A5 JP 2007530584 A5 JP2007530584 A5 JP 2007530584A5 JP 2007505204 A JP2007505204 A JP 2007505204A JP 2007505204 A JP2007505204 A JP 2007505204A JP 2007530584 A5 JP2007530584 A5 JP 2007530584A5
Authority
JP
Japan
Prior art keywords
composition
antibody
cancer
integrin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007505204A
Other languages
English (en)
Japanese (ja)
Other versions
JP4857259B2 (ja
JP2007530584A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009939 external-priority patent/WO2005092073A2/en
Publication of JP2007530584A publication Critical patent/JP2007530584A/ja
Publication of JP2007530584A5 publication Critical patent/JP2007530584A5/ja
Application granted granted Critical
Publication of JP4857259B2 publication Critical patent/JP4857259B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007505204A 2004-03-24 2005-03-24 癌細胞増殖を阻害するための抗α５β１抗体の使用 Expired - Fee Related JP4857259B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US55642204P 2004-03-24 2004-03-24
US55642104P 2004-03-24 2004-03-24
US60/556,421 2004-03-24
US60/556,422 2004-03-24
US62504904P 2004-11-03 2004-11-03
US60/625,049 2004-11-03
US65109805P 2005-02-07 2005-02-07
US60/651,098 2005-02-07
US65751405P 2005-02-28 2005-02-28
US60/657,514 2005-02-28
PCT/US2005/009939 WO2005092073A2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Publications (3)

Publication Number Publication Date
JP2007530584A JP2007530584A (ja) 2007-11-01
JP2007530584A5 true JP2007530584A5 (enExample) 2008-05-08
JP4857259B2 JP4857259B2 (ja) 2012-01-18

Family

ID=35056776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505204A Expired - Fee Related JP4857259B2 (ja) 2004-03-24 2005-03-24 癌細胞増殖を阻害するための抗α５β１抗体の使用

Country Status (14)

Country Link
US (2) US7662384B2 (enExample)
EP (1) EP1755659B1 (enExample)
JP (1) JP4857259B2 (enExample)
KR (1) KR20070009637A (enExample)
AT (1) ATE531388T1 (enExample)
AU (1) AU2005226736B2 (enExample)
BR (1) BRPI0509177A (enExample)
CA (1) CA2560508A1 (enExample)
DK (1) DK1755659T3 (enExample)
ES (1) ES2376556T3 (enExample)
IL (1) IL178042A (enExample)
NO (1) NO20064794L (enExample)
NZ (1) NZ549893A (enExample)
WO (1) WO2005092073A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP1989231B1 (en) * 2006-03-21 2015-05-20 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
EP2032605A2 (en) * 2006-05-24 2009-03-11 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
US20100150931A1 (en) * 2006-11-22 2010-06-17 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
US20090041767A1 (en) * 2007-07-27 2009-02-12 Vanitha Ramakrishnan Pharmaceutical combinations
PE20091029A1 (es) 2007-09-26 2009-08-19 Genentech Inc Anticuerpos anti-alfa 5 beta 1
CA2714071A1 (en) * 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
HK1198689A1 (en) 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
NO2760138T3 (enExample) 2012-10-01 2018-08-04
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
WO2025106724A2 (en) * 2023-11-15 2025-05-22 Morphic Therapeutic, Inc. USE OF ANTI-α5β1 ANTIBODIES IN THE TREATMENT OF PULMONARY HYPERTENSION AND HEART FAILURE
WO2025106725A2 (en) * 2023-11-15 2025-05-22 Morphic Therapeutic, Inc. HUMAN ANTI-α5β1 ANTIBODIES AND USES THEREOF

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5863537A (en) 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU673865B2 (en) 1992-10-29 1996-11-28 Australian National University, The Angiogenesis inhibitory antibodies
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
DE69516351T2 (de) * 1994-09-21 2000-12-07 Matsushita Electric Industrial Co., Ltd. Sekundäre Lithium Feststoffbatterie
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
EP0888344A1 (en) 1996-03-15 1999-01-07 The Du Pont Merck Pharmaceutical Company Spirocycle integrin inhibitors
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
CA2250291A1 (en) 1997-01-29 1998-07-30 Toray Industries Inc. Chimeric proteins, their heterodimer complexes, and platelet substitutes
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
CA2330277A1 (en) 1998-04-27 1999-11-04 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP1075277B2 (en) * 1998-05-08 2012-10-31 The Regents of the University of California Methods for detecting and inhibiting angiogenesis
EP1204764A2 (en) 1999-08-11 2002-05-15 EOS Biotechnology, Inc. Methods of screening for angiogenesis modulators
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20040259152A1 (en) 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
WO2002079492A2 (en) 2001-02-14 2002-10-10 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
NZ540562A (en) 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
MX342007B (es) 2003-05-14 2016-09-09 Immunogen Inc Composicion de farmaco conjugado.

Similar Documents

Publication Publication Date Title
JP2007530584A5 (enExample)
Beatty et al. The biological underpinnings of therapeutic resistance in pancreatic cancer
RU2007127842A (ru) Антитела против ангиопоэтина-2 и их применение
Stillebroer et al. Phase 1 radioimmunotherapy study with lutetium 177–labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma
RU2019101632A (ru) Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
Scott et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer
ES2281978T3 (es) Uso de un antagonista del receptor at-1 o de un modulador del receptor at-2 para tratar enfermedades asociadas con un incremento de los receptores at-1 o at-2.
Chaudhry et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer
Persson et al. First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts
JP2007504280A5 (enExample)
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
JP2009539380A5 (enExample)
Wichert et al. Targeting carbonic anhydrase IX with small organic ligands
JP2011506274A5 (enExample)
EP2268604A1 (en) Therapies for cancer using isotopically substituted lysine
JP2020536096A5 (enExample)
JP2010534685A (ja) チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ
Toyota et al. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model
WO2021129616A1 (zh) 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
AU2003229431B2 (en) Method for reducing pain using oncolytic viruses
JP2011504361A (ja) 肝細胞癌細胞に特異的なペプチドおよびその適用
Noda et al. Pharmacokinetic/pharmacodynamic analysis of a hemodialyzed patient treated with 25 mg of sunitinib
RU2006137360A (ru) ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
Ferrone et al. A human high molecular weight-melanoma associated antigen (HMW-MAA) defined by monoclonal antibodies: a useful marker to radioimage tumor lesions in patients with melanoma
JP2009538935A5 (enExample)